TOKYO, Mar 19 (Pulse News Wire) – D.Western Therapeutics Institute, Inc. (4576.T) completed the observation period for its global Phase III clinical trial of K-321, a rho kinase inhibitor eye drop designed to treat Fuchs' corneal endothelial dystrophy.
The trial, conducted across multiple countries including the United States and Europe, aimed to evaluate the efficacy and safety of K-321 compared to placebo. With the completion of this final trial, all observation periods for the global Phase III clinical trials have been concluded. Data collection and statistical analysis will now proceed, and results will be communicated promptly upon availability. Manufacturing and marketing approval is anticipated for 2027.
Fuchs' corneal endothelial dystrophy leads to corneal endothelial damage and severe visual impairment. Current treatments such as cornea transplantation highlight the need for effective drug therapies. D.Western Therapeutics and its partner Kyowa Hakko Kirin aim to offer patients a new treatment option through the development of K-321. There are no changes expected to the company's fiscal year 2026 earnings forecast due to this development.
🟢 Confidence: High AI-translated content.